Bone marrow transplant for a boy with alpha-mannosidosis illustrates a family’s decision-making in rare diseases

Clara van Karnebeek, Mary Dunbar, Jeff Davis, Kristin Bowden, Kevin Chaplin, Robin Chaplin, Dina McConnell, Paul Moxham, Millan S. Patel, Paul Steinbok, Hilary Vallance, Sylvia Stockler

Abstract


Abstract:

Decision making regarding treatment of rare diseases can pose a unique challenge given the limited availability of evidence. Here we present a case of a Caucasian male who was diagnosed at age 5 years with alpha-mannosidosis, an autosomal recessive lysosomal disorder of glycoprotein metabolism, suspected based on signs of sensorineural hearing loss and apparent skeletal malformation (thickening of the cranial vault and frontal bossing, bone hyperplasia causing facial coarsening, pectus carinatum and hypertelorism). Diagnosis was confirmed based on deficient leucocyte alpha-mannosidase activity (15.5 nmol/hr/mg protein, normal range 245-625), and molecular analysis of the MAN2B1 gene, which revealed c.384G>A (p.W128X) and c.2248C>T (p.R750W) mutations. Parents made use of social media and other Internet resources to educate themselves and connect with experts and other parents of children with alpha-mannosidosis to aid decision-making regarding treatment. In 2009, the patient underwent matched sibling allogeneic bone marrow transplantation from a heterozygous carrier sibling donor, which resulted in normalization of leuococyte alpha-mannosidase activity and significant improvements in hearing, coordination and motor skills, cognitive abilities, and brain pathology. The ability of digital media and use of new technologies linking patients, their families and care-providers in decision-making networks for rare diseases is discussed.

 


Keywords


mannosidase deficiency diseases, bone marrow transplantation, medical decision making, Internet, high risk treatment, heterozygote donor, social media

Full Text:

PDF

References


Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet Journal of Rare Diseases. 2008;3(1).

Aronson NN, Kuranda MJ. LYSOSOMAL DEGRADATION OF ASN-LINKED GLYCOPROTEINS. Faseb Journal.

;3(14):2615-22.

Riise Stensland HMF, Klenow HB, Van Nguyen L, Hansen GM, Malm D, Nilssen O. Identification of 83 novel alpha-manno- sidosis-associated sequence variants: functional analysis of MAN2B1 missense mutations. Human mutation. 2012;33(3):511- 20.

Berg T, Riise HMF, Hansen GN, Malm D, Tranebjaerg L, Tollersrud OK, et al. Spectrum of mutations in alpha-mannosidosis. American Journal of Human Genetics. 1999;64(1):77-88.

Beck M, Olsen KJ, Wraith JE, Zeman J, Michalski J-C, Saftig P, et al. Natural history of alpha mannosidosis a longitudinal study. Orphanet Journal of Rare Diseases. 2013;8(1).

Malm D, Riise Stensland HMF, Edvardsen Ø, Nilssen Ø. The natural course and complications of alpha-mannosidosis-a retrospective and descriptive study. Journal of the Neurological Sciences. 2013 Jun 6.

Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. The Lancet. 1981;2(8249):709-12.

Will A, Cooper A, Hatton C, Sardharwalla IB, Evans DIK, Stevens RF. BONE-MARROW TRANSPLANTATION IN THE TREATMENT OF ALPHA-MANNOSIDOSIS. Archives of Disease in Childhood. 1987;62(10):1044-9.

Wall DA, Grange DK, Goulding P, Daines M, Luisiri A, Kotagel S. Bone marrow transplantation for the treatment of alpha- mannosidosis. Journal of Pediatrics. 1998;133(2):282-5.

Grewal SS, Shapiro EG, Krivit W, Charnas L, Lockman LA, Delaney KA, et al. Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation. Journal of Pediatrics. 2004;144(5):569-73.

Mynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, et al. Allogeneic hematopoietic SCT for alpha-manno- sidosis: an analysis of 17 patients. Bone Marrow Transplantation. 2012;47(3):352-9.

Blanz J, Stroobants S, Luellmann-Rauch R, Morelle W, Luedemann M, D’Hooge R, et al. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Human Molecular Genetics. 2008;17(22):3437-45.

Borgwardt L, Dali CI, Fogh J, Månsson JE, Olsen KJ, Beck HC, et al. Enzyme replacement therapy for alpha-mannosidosis: 12 months follow-up of a single centre, randomised, multiple dose study. Journal of the Neurological Sciences. 2013 Mar 14.

Yabe H, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, Koike T, et al. Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents. International Journal of Hematology. 2004;80(1):78-82.

Albert MH, Schuster F, Peters C, Schulze S, Pontz BF, Muntau AC, et al. T-cell-depleted peripheral blood stem cell trans- plantation for alpha-mannosidosis. Bone Marrow Transplantation. 2003;32(4):443-6.

Church H, Tylee K, Cooper A, Thornley M, Mercer J, Wraith E, et al. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplantation. 2007;39(4):207-10.

van Karnebeek CDM, Shevell M, Zschocke J, Moeschler JB, Stockler S. The metabolic evaluation of the child with an intel- lectual developmental disorder: Diagnostic algorithm for identification of treatable causes and new digital resource. Molecu- lar Genetics and Metabolism. 2014 Jan 24. pii: S1096-7192(14)00037-7. doi: 10.1016/j.ymgme.2014.01.011. [Epub ahead of print]

Van Karnebeek CDM, Houben RFA, Lafek M, Giannasi W, Stockler S. The treatable intellectual disability APP www.treat- able-id.org: A digital tool to enhance diagnosis & care for rare diseases. Orphanet Journal of Rare Diseases. 2012;7(1).

Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, et al. Newborn screening for lysosomal storage disor- ders. Molecular Genetics and Metabolism. 2006;88(4):307-14.

Moorhead SA, Hazlett DE, Harrison L, Carroll JK, Irwin A, Hoving C. A New Dimension of Health Care: Systematic Review of the Uses, Benefits, and Limitations of Social Media for Health Communication. Journal of Medical Internet Research. 2013;15(4).

Tozzi AE, Mingarelli R, Agricola E, Gonfiantini M, Pandolfi E, Carloni E, et al. The internet user profile of Italian families of

patients with rare diseases: a web survey. Orphanet Journal of Rare Diseases. 2013;8(1).

Limb L, Nutt S, Sen A, UK RD. Experiences of Rare Diseases. 2010. http://books.google.ca/books?id=z11uMwEACAAJ&d

q=inauthor:limb+inauthor:nutt&hl=&cd=1&source=gbs_api